Clearmind Medicine Announces Board Leadership Changes and $10 Million Increase in Financing Capacity

Clearmind Medicine Inc. announced significant updates regarding its board of directors and financing arrangements in an April 30, 2026, SEC filing. On April 26, 2026, Mr. Amitay Weiss resigned as Chairman of the Board, effective immediately. Following his departure, the Board appointed Ms. Hila Kiron-Revach as the new Chairperson on April 27, 2026. Additionally, Mr. Asaf Itzhaik was appointed to the compensation, nominating, and corporate governance committees. The Board confirmed that Ms. Kiron-Revach, Mr. Itzhaik, and Mr. Yehonatan Shachar meet Nasdaq's independence requirements. Parallel to these leadership changes, Clearmind entered into an amendment to its September 2025 Securities Purchase Agreement (SPA). The amendment increases the available subscription capacity for convertible promissory notes, providing an additional $10,000,000 for future issuances. Under the revised terms, the company can issue up to $2,500,000 in notes per calendar quarter. This move ensures continued access to capital as the original subscription amount had been substantially utilized. The company maintains no obligation to draw down the remaining funds.